Strongbridge Biopharma plc announced earnings results for the fourth quarter ended December 31, 2020. For the fourth quarter, the company announced total revenue was USD 8.071 million compared to USD 5.684 million a year ago. Operating loss was USD 9.584 million compared to USD 16.930 million a year ago. Net loss was USD 2.636 million compared to USD 15.515 million a year ago. Basic loss per share from continuing operations was USD 0.06 compared to USD 0.25 a year ago. Diluted loss per share from continuing operations was USD 0.18 compared to USD 0.31 a year ago. For the full year, total revenue was USD 30.731 million compared to USD 21.712 million a year ago. Operating loss was USD 43.165 million compared to USD 67.093 million a year ago. Net loss was USD 45.075 million compared to USD 49.451 million a year ago. Basic loss per share from continuing operations was USD 0.78 compared to USD 0.91 a year ago. Diluted loss per share from continuing operations was USD 0.78 compared to USD 1.1 a year ago.